US20020177688A1
(en)
*
|
1988-12-22 |
2002-11-28 |
Kirin-Amgen, Inc., |
Chemically-modified G-CSF
|
JP2989002B2
(en)
*
|
1988-12-22 |
1999-12-13 |
キリン―アムジエン・インコーポレーテツド |
Chemically modified granulocyte colony stimulating factor
|
US5581476A
(en)
*
|
1993-01-28 |
1996-12-03 |
Amgen Inc. |
Computer-based methods and articles of manufacture for preparing G-CSF analogs
|
US5951974A
(en)
*
|
1993-11-10 |
1999-09-14 |
Enzon, Inc. |
Interferon polymer conjugates
|
ES2251924T3
(en)
*
|
1994-02-08 |
2006-05-16 |
Amgen Inc. |
ORAL ADMINISTRATION OF CHEMICALLY MODIFIED PROTEINS.
|
US6429290B1
(en)
|
1994-08-17 |
2002-08-06 |
The Rockefeller University |
OB polypeptides, modified forms and derivatives
|
US6001968A
(en)
|
1994-08-17 |
1999-12-14 |
The Rockefeller University |
OB polypeptides, modified forms and compositions
|
US20030053982A1
(en)
*
|
1994-09-26 |
2003-03-20 |
Kinstler Olaf B. |
N-terminally chemically modified protein compositions and methods
|
US5824784A
(en)
|
1994-10-12 |
1998-10-20 |
Amgen Inc. |
N-terminally chemically modified protein compositions and methods
|
WO1996041813A2
(en)
*
|
1994-11-09 |
1996-12-27 |
Offord Robin E |
Functionalized polymers for site-specific attachment
|
US6008202A
(en)
*
|
1995-01-23 |
1999-12-28 |
University Of Pittsburgh |
Stable lipid-comprising drug delivery complexes and methods for their production
|
US5795587A
(en)
|
1995-01-23 |
1998-08-18 |
University Of Pittsburgh |
Stable lipid-comprising drug delivery complexes and methods for their production
|
US5908621A
(en)
*
|
1995-11-02 |
1999-06-01 |
Schering Corporation |
Polyethylene glycol modified interferon therapy
|
EP0858343B1
(en)
|
1995-11-02 |
2004-03-31 |
Schering Corporation |
Continuous low-dose cytokine infusion therapy
|
TW517067B
(en)
|
1996-05-31 |
2003-01-11 |
Hoffmann La Roche |
Interferon conjugates
|
CA2273852C
(en)
|
1996-12-06 |
2009-09-29 |
Amgen Inc. |
Combination therapy using an il-1 inhibitor for treating il-1 mediated diseases
|
ATE200030T1
(en)
*
|
1997-01-29 |
2001-04-15 |
Polymasc Pharmaceuticals Plc |
PEGYLATION PROCEDURE
|
US6583267B2
(en)
|
1997-06-06 |
2003-06-24 |
Kyowa Hakko Kogyo Co., Ltd. |
Chemically modified polypeptides
|
BR9812267B1
(en)
*
|
1997-07-14 |
2013-11-26 |
|
Recombinant Growth Hormone.
|
US20080076706A1
(en)
*
|
1997-07-14 |
2008-03-27 |
Bolder Biotechnology, Inc. |
Derivatives of Growth Hormone and Related Proteins, and Methods of Use Thereof
|
US6753165B1
(en)
*
|
1999-01-14 |
2004-06-22 |
Bolder Biotechnology, Inc. |
Methods for making proteins containing free cysteine residues
|
US6017876A
(en)
*
|
1997-08-15 |
2000-01-25 |
Amgen Inc. |
Chemical modification of granulocyte-colony stimulating factor (G-CSF) bioactivity
|
US5985263A
(en)
*
|
1997-12-19 |
1999-11-16 |
Enzon, Inc. |
Substantially pure histidine-linked protein polymer conjugates
|
US5981709A
(en)
*
|
1997-12-19 |
1999-11-09 |
Enzon, Inc. |
α-interferon-polymer-conjugates having enhanced biological activity and methods of preparing the same
|
IL139286A
(en)
|
1998-04-28 |
2005-12-18 |
Applied Research Systems |
Polyol-ifn-beta conjugates, their preparation and use
|
CN1230198C
(en)
*
|
1998-05-15 |
2005-12-07 |
先灵公司 |
Combination therapy comprising ribavirin and interferon alpha in antiviral treatment naive patients having G chronic hepatitis C infection
|
NL1009601C2
(en)
*
|
1998-07-09 |
2000-01-11 |
Univ Utrecht |
Compound which can inhibit the binding of a protein to mast cells, use of the compound for the preparation of a medicament, a pharmaceutical preparation, a method of diagnosing a disease and a selection method.
|
MXPA01000481A
(en)
*
|
1998-07-16 |
2002-11-29 |
Hyseq Inc |
Methods and materials relating to novel cd39-like polypeptides.
|
DK2316475T3
(en)
|
1998-08-06 |
2017-11-20 |
Mountain View Pharmaceuticals Inc |
Isolated tetrameric uricase
|
US6783965B1
(en)
*
|
2000-02-10 |
2004-08-31 |
Mountain View Pharmaceuticals, Inc. |
Aggregate-free urate oxidase for preparation of non-immunogenic polymer conjugates
|
US6420339B1
(en)
|
1998-10-14 |
2002-07-16 |
Amgen Inc. |
Site-directed dual pegylation of proteins for improved bioactivity and biocompatibility
|
EE04967B1
(en)
*
|
1998-10-16 |
2008-02-15 |
Biogen, Incorporated |
Glycylated Interferon Beta, its Use and a Pharmaceutical Composition, Method for Prolonging Interferon Beta-1a Activity, and Preparing a Protein of the Invention
|
MXPA01003790A
(en)
*
|
1998-10-16 |
2002-09-18 |
Biogen Inc |
Interferon-beta fusion proteins and uses.
|
DE69934425T2
(en)
*
|
1998-10-23 |
2007-09-27 |
Amgen Inc., Thousand Oaks |
THROMBOPOIETIN SUBSTITUTE
|
US7488590B2
(en)
|
1998-10-23 |
2009-02-10 |
Amgen Inc. |
Modified peptides as therapeutic agents
|
US6660843B1
(en)
|
1998-10-23 |
2003-12-09 |
Amgen Inc. |
Modified peptides as therapeutic agents
|
JP2002531089A
(en)
*
|
1998-11-30 |
2002-09-24 |
イーライ・リリー・アンド・カンパニー |
Erythropoietic compounds
|
CN1210400C
(en)
|
1999-01-14 |
2005-07-13 |
博尔德生物技术公司 |
Methods for making proteins containing free cysteine residues
|
US8288126B2
(en)
|
1999-01-14 |
2012-10-16 |
Bolder Biotechnology, Inc. |
Methods for making proteins containing free cysteine residues
|
EP1369429A1
(en)
*
|
1999-01-29 |
2003-12-10 |
F. Hoffmann-La Roche Ag |
GCSF conjugates
|
DK1157037T3
(en)
*
|
1999-01-29 |
2003-11-24 |
Hoffmann La Roche |
G-CSF-conjugates
|
WO2000051626A1
(en)
*
|
1999-03-01 |
2000-09-08 |
Kyowa Hakko Kogyo Co., Ltd. |
Chemically modified g-csf preparations
|
US6485718B1
(en)
*
|
1999-04-13 |
2002-11-26 |
Pharmacia Corporation |
Site specific ligation of proteins to synthetic particles
|
US6924264B1
(en)
*
|
1999-04-30 |
2005-08-02 |
Amylin Pharmaceuticals, Inc. |
Modified exendins and exendin agonists
|
US8106098B2
(en)
*
|
1999-08-09 |
2012-01-31 |
The General Hospital Corporation |
Protein conjugates with a water-soluble biocompatible, biodegradable polymer
|
US7459540B1
(en)
|
1999-09-07 |
2008-12-02 |
Amgen Inc. |
Fibroblast growth factor-like polypeptides
|
US7074878B1
(en)
|
1999-12-10 |
2006-07-11 |
Harris J Milton |
Hydrolytically degradable polymers and hydrogels made therefrom
|
US6348558B1
(en)
|
1999-12-10 |
2002-02-19 |
Shearwater Corporation |
Hydrolytically degradable polymers and hydrogels made therefrom
|
US6555660B2
(en)
*
|
2000-01-10 |
2003-04-29 |
Maxygen Holdings Ltd. |
G-CSF conjugates
|
US6831158B2
(en)
*
|
2000-01-10 |
2004-12-14 |
Maxygen Holdings Ltd. |
G-CSF conjugates
|
AU782580B2
(en)
|
2000-01-10 |
2005-08-11 |
Maxygen, Inc. |
G-CSF conjugates
|
US6646110B2
(en)
*
|
2000-01-10 |
2003-11-11 |
Maxygen Holdings Ltd. |
G-CSF polypeptides and conjugates
|
DK1257295T3
(en)
|
2000-02-11 |
2009-08-10 |
Bayer Healthcare Llc |
Factor VII or VIIA-like molecules
|
US7049761B2
(en)
*
|
2000-02-11 |
2006-05-23 |
Altair Engineering, Inc. |
Light tube and power supply circuit
|
CA2337661A1
(en)
|
2000-02-29 |
2001-08-29 |
Pfizer Products Inc. |
Stabilized granulocyte colony stimulating factor
|
US20020064820A1
(en)
*
|
2000-03-13 |
2002-05-30 |
Jean-Michel Dayer |
Apo-A-I regulation of T-cell signaling
|
AU2001289307A1
(en)
*
|
2000-04-06 |
2001-10-23 |
Pharmacia Corporation |
Chemically-modified myelopoietin conjugates
|
US6586398B1
(en)
*
|
2000-04-07 |
2003-07-01 |
Amgen, Inc. |
Chemically modified novel erythropoietin stimulating protein compositions and methods
|
EP1280924A2
(en)
*
|
2000-04-14 |
2003-02-05 |
University of South Carolina Research Foundation |
Cloning of corynebacteriaceae histidine ammonia lyase and therapeutic uses
|
WO2001081376A2
(en)
|
2000-04-21 |
2001-11-01 |
Amgen Inc. |
Apo-ai/aii peptide derivatives
|
US6677136B2
(en)
|
2000-05-03 |
2004-01-13 |
Amgen Inc. |
Glucagon antagonists
|
US20030211094A1
(en)
*
|
2001-06-26 |
2003-11-13 |
Nelsestuen Gary L. |
High molecular weight derivatives of vitamin k-dependent polypeptides
|
KR20030036591A
(en)
*
|
2000-07-12 |
2003-05-09 |
그리폰 테라퓨틱스, 인코포레이티드 |
Polymer-modified bioactive synthetic chemokines, and methods for their manufacture and use
|
WO2002019963A2
(en)
*
|
2000-09-08 |
2002-03-14 |
Gryphon Therapeutics, Inc. |
Synthetic erythropoiesis stimulating proteins
|
US7118737B2
(en)
*
|
2000-09-08 |
2006-10-10 |
Amylin Pharmaceuticals, Inc. |
Polymer-modified synthetic proteins
|
EP1324779B1
(en)
|
2000-09-29 |
2011-07-20 |
Schering Corporation |
Pegylated interleukin-10
|
ATE421535T1
(en)
*
|
2000-10-16 |
2009-02-15 |
Chugai Pharmaceutical Co Ltd |
PEG-MODIFIED ERYTHROPOIETIN
|
ATE537845T1
(en)
*
|
2000-10-31 |
2012-01-15 |
Pr Pharmaceuticals Inc |
METHOD FOR PRODUCING FORMULATIONS FOR IMPROVED DELIVERY OF BIOACTIVE MOLECULES
|
WO2002036626A1
(en)
*
|
2000-11-02 |
2002-05-10 |
Maxygen Aps |
Single-chain multimeric polypeptides
|
CN1321134C
(en)
*
|
2000-11-23 |
2007-06-13 |
赵剑 |
Hetergeneous product of bio-active protein and its preparing process
|
AU2002230843B8
(en)
*
|
2000-12-14 |
2007-05-17 |
Amylin Pharmaceuticals, Llc |
Peptide YY and peptide YY agonists for treatment of metabolic disorders
|
TW593427B
(en)
*
|
2000-12-18 |
2004-06-21 |
Nektar Therapeutics Al Corp |
Synthesis of high molecular weight non-peptidic polymer derivatives
|
US7053150B2
(en)
*
|
2000-12-18 |
2006-05-30 |
Nektar Therapeutics Al, Corporation |
Segmented polymers and their conjugates
|
AU3323002A
(en)
*
|
2000-12-20 |
2002-07-01 |
Hoffmann La Roche |
Erythropoietin conjugates
|
US7442370B2
(en)
|
2001-02-01 |
2008-10-28 |
Biogen Idec Ma Inc. |
Polymer conjugates of mutated neublastin
|
CN1514844A
(en)
*
|
2001-02-06 |
2004-07-21 |
Ĭ��ר������˾ |
Modified granulocyte colony stimulating factor (G-CSF) with reduced immunogenicity
|
EP1234583A1
(en)
*
|
2001-02-23 |
2002-08-28 |
F. Hoffmann-La Roche Ag |
PEG-conjugates of HGF-NK4
|
EP1366075B1
(en)
|
2001-02-27 |
2009-05-27 |
Maxygen Aps |
New interferon beta-like molecules
|
US7276580B2
(en)
|
2001-03-12 |
2007-10-02 |
Biogen Idec Ma Inc. |
Neurotrophic factors
|
US7247618B2
(en)
*
|
2001-04-30 |
2007-07-24 |
Tripathi Rajavashisth |
Methods for inhibiting macrophage colony stimulating factor and c-FMS-dependent cell signaling
|
AU2002256398A2
(en)
*
|
2001-04-30 |
2002-11-11 |
Targeted Genetics Corporation |
Lipid-comprising drug delivery complexes and methods for their production
|
EE05294B1
(en)
|
2001-05-11 |
2010-04-15 |
Amgen Inc. |
TALL-1 binding agent composition
|
WO2003002716A2
(en)
*
|
2001-06-28 |
2003-01-09 |
Mountain View Pharmaceuticals, Inc. |
Polymer stabilized proteinases
|
ATE468862T1
(en)
*
|
2001-07-11 |
2010-06-15 |
Maxygen Inc |
G-CSF CONJUGATES
|
US20040077835A1
(en)
*
|
2001-07-12 |
2004-04-22 |
Robin Offord |
Chemokine receptor modulators, production and use
|
US20050063949A1
(en)
*
|
2001-10-05 |
2005-03-24 |
Gary Visor |
Method of treating hepatitis virus infection with a multiphasic interferon delivery profile
|
US7084257B2
(en)
|
2001-10-05 |
2006-08-01 |
Amgen Inc. |
Fully human antibody Fab fragments with human interferon-gamma neutralizing activity
|
US6908963B2
(en)
*
|
2001-10-09 |
2005-06-21 |
Nektar Therapeutics Al, Corporation |
Thioester polymer derivatives and method of modifying the N-terminus of a polypeptide therewith
|
US7173003B2
(en)
|
2001-10-10 |
2007-02-06 |
Neose Technologies, Inc. |
Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF
|
US7157277B2
(en)
|
2001-11-28 |
2007-01-02 |
Neose Technologies, Inc. |
Factor VIII remodeling and glycoconjugation of Factor VIII
|
US7214660B2
(en)
*
|
2001-10-10 |
2007-05-08 |
Neose Technologies, Inc. |
Erythropoietin: remodeling and glycoconjugation of erythropoietin
|
US7138370B2
(en)
|
2001-10-11 |
2006-11-21 |
Amgen Inc. |
Specific binding agents of human angiopoietin-2
|
DK2939696T3
(en)
|
2001-10-18 |
2016-05-23 |
Nektar Therapeutics |
Polymer Conjugates of Opioid Antagonists
|
WO2003043651A1
(en)
*
|
2001-11-19 |
2003-05-30 |
Kyowa Hakko Kogyo Co., Ltd. |
Drug mobilizing pluripotent stem cells from tissue into peripheral blood
|
US20030171285A1
(en)
*
|
2001-11-20 |
2003-09-11 |
Finn Rory F. |
Chemically-modified human growth hormone conjugates
|
AU2002356990A1
(en)
*
|
2001-11-20 |
2003-06-10 |
Pharmacia Corporation |
Chemically-modified human growth hormone conjugates
|
KR100480432B1
(en)
*
|
2001-12-04 |
2005-04-06 |
선바이오(주) |
Conjugates of granulocyte-colony stimulating factor and polyethylene glycol derivatives
|
WO2003049760A1
(en)
*
|
2001-12-07 |
2003-06-19 |
Intermune, Inc. |
Compositions and method for treating hepatitis virus infection
|
DE60323936D1
(en)
*
|
2002-01-14 |
2008-11-20 |
Gen Hospital Corp |
BIOABEAABLE POLYCETALES, METHOD FOR THE PRODUCTION THEREOF, AND THEIR USE
|
PL213322B1
(en)
|
2002-01-18 |
2013-02-28 |
Biogen Idec Inc |
Polyalkylene polymer compounds and uses thereof
|
DE10209821A1
(en)
|
2002-03-06 |
2003-09-25 |
Biotechnologie Ges Mittelhesse |
Coupling of proteins to a modified polysaccharide
|
US20030191056A1
(en)
|
2002-04-04 |
2003-10-09 |
Kenneth Walker |
Use of transthyretin peptide/protein fusions to increase the serum half-life of pharmacologically active peptides/proteins
|
US20030199464A1
(en)
*
|
2002-04-23 |
2003-10-23 |
Silviu Itescu |
Regeneration of endogenous myocardial tissue by induction of neovascularization
|
AU2003243545A1
(en)
*
|
2002-06-14 |
2003-12-31 |
Amylin Pharmaceuticals, Inc. |
Prevention and/or treatment of inflammatory bowel disease using pyy or agonists thereof
|
US20040002451A1
(en)
*
|
2002-06-20 |
2004-01-01 |
Bruce Kerwin |
Compositions of pegylated soluble tumor necrosis factor receptors and methods of preparing
|
AU2003256613A1
(en)
*
|
2002-07-19 |
2004-02-09 |
Amgen Inc. |
Protein conjugates with a water-soluble biocompatible, biogradable polymer
|
CA2492803C
(en)
*
|
2002-07-19 |
2013-11-05 |
The General Hospital Corporation |
Oxime conjugates and methods for their formation and use
|
PL376536A1
(en)
|
2002-08-28 |
2006-01-09 |
Immunex Corporation |
Compositions and methods for treating cardiovascular disease
|
RS20050202A
(en)
*
|
2002-09-09 |
2007-08-03 |
Nektar Therapeuticals Al.Corporation, |
Water-soluble polymer alkanals
|
US8129330B2
(en)
|
2002-09-30 |
2012-03-06 |
Mountain View Pharmaceuticals, Inc. |
Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof
|
JP2004196770A
(en)
*
|
2002-10-24 |
2004-07-15 |
Effector Cell Institute Inc |
Agent for increasing blood level of dendritic cell precursor
|
US20050075279A1
(en)
*
|
2002-10-25 |
2005-04-07 |
Boehringer Ingelheim International Gmbh |
Macrocyclic peptides active against the hepatitis C virus
|
US7314613B2
(en)
|
2002-11-18 |
2008-01-01 |
Maxygen, Inc. |
Interferon-alpha polypeptides and conjugates
|
TWI281864B
(en)
*
|
2002-11-20 |
2007-06-01 |
Pharmacia Corp |
N-terminally monopegylated human growth hormone conjugates and process for their preparation
|
EA013535B1
(en)
|
2002-12-26 |
2010-06-30 |
Маунтин Вью Фамэсьютикэлс, Инк. |
Polymer conjugate of bioactive component (variants), method for producing and use thereof, pharmaceutical products on the base thereof
|
EP1667708B9
(en)
*
|
2002-12-26 |
2012-10-31 |
Mountain View Pharmaceuticals, Inc. |
POLYETHYLENE GLYCOL CONJUGATES OF INTERFERON-BETA-1b WITH ENHANCED IN VITRO BIOLOGICAL POTENCY
|
CN1761680A
(en)
|
2002-12-26 |
2006-04-19 |
武田药品工业株式会社 |
Metastin derivative and use thereof
|
EP1616003A4
(en)
*
|
2002-12-30 |
2007-06-20 |
Gryphon Therapeutics Inc |
Water-soluble thioester and selenoester compounds and methods for making and using the same
|
US7803362B2
(en)
*
|
2003-01-24 |
2010-09-28 |
Synageva Biopharma Corp. |
Glycosylated interferon alpha
|
CA2516552A1
(en)
*
|
2003-02-26 |
2004-09-10 |
Intermune, Inc. |
Polyethylene glycol modified interferon compositions and methods of use thereof
|
US20070077225A1
(en)
*
|
2003-02-28 |
2007-04-05 |
Blatt Lawrence M |
Continuous delivery methods for treating hepatitis virus infection
|
EP2405015B1
(en)
|
2003-03-05 |
2016-01-06 |
Halozyme, Inc. |
Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof
|
US20060104968A1
(en)
|
2003-03-05 |
2006-05-18 |
Halozyme, Inc. |
Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
|
US7871607B2
(en)
|
2003-03-05 |
2011-01-18 |
Halozyme, Inc. |
Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
|
CA2519092C
(en)
|
2003-03-14 |
2014-08-05 |
Neose Technologies, Inc. |
Branched water-soluble polymers and their conjugates
|
US20060134736A1
(en)
*
|
2003-03-28 |
2006-06-22 |
Jacobs John W |
Human growth hormone conjugated with biocompatible polymer
|
MXPA05010411A
(en)
*
|
2003-03-28 |
2006-05-31 |
Biopolymed Inc |
Biologically active material conjugated with biocompatible polymer with 1:1 complex, preparation method thereof and pharmaceutical composition comprising the same.
|
US7642340B2
(en)
|
2003-03-31 |
2010-01-05 |
Xencor, Inc. |
PEGylated TNF-α variant proteins
|
US7610156B2
(en)
|
2003-03-31 |
2009-10-27 |
Xencor, Inc. |
Methods for rational pegylation of proteins
|
US7587286B2
(en)
|
2003-03-31 |
2009-09-08 |
Xencor, Inc. |
Methods for rational pegylation of proteins
|
US20070026485A1
(en)
|
2003-04-09 |
2007-02-01 |
Neose Technologies, Inc. |
Glycopegylation methods and proteins/peptides produced by the methods
|
US8791070B2
(en)
|
2003-04-09 |
2014-07-29 |
Novo Nordisk A/S |
Glycopegylated factor IX
|
DK2599502T3
(en)
*
|
2003-04-11 |
2017-04-18 |
Antriabio Inc |
Process for Preparation of Site-Specific Protein Conjugates
|
JP4753867B2
(en)
|
2003-04-15 |
2011-08-24 |
グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー |
Conjugates containing human IL-18 and substitutional variants thereof
|
EP1618179B1
(en)
|
2003-04-18 |
2014-05-07 |
Biogen Idec MA Inc. |
Polymer-conjugated glycosylated neublastin
|
EP2390262A1
(en)
|
2003-05-16 |
2011-11-30 |
Intermune, Inc. |
Synthetic chemokine receptor ligands and methods of use thereof
|
AU2004259327B2
(en)
|
2003-07-22 |
2009-12-17 |
Nektar Therapeutics |
Method for preparing functionalized polymers from polymer alcohols
|
US9005625B2
(en)
|
2003-07-25 |
2015-04-14 |
Novo Nordisk A/S |
Antibody toxin conjugates
|
ATE554108T1
(en)
|
2003-07-25 |
2012-05-15 |
Amgen Inc |
PROCEDURES REGARDING LDCAM AND CRTAM
|
WO2005014655A2
(en)
|
2003-08-08 |
2005-02-17 |
Fresenius Kabi Deutschland Gmbh |
Conjugates of hydroxyalkyl starch and a protein
|
CA2536643C
(en)
*
|
2003-08-25 |
2013-11-12 |
Toray Industries, Inc. |
Interferon-.beta. complex
|
GB0320638D0
(en)
|
2003-09-03 |
2003-10-01 |
Novartis Ag |
Organic compounds
|
KR20120073370A
(en)
|
2003-09-17 |
2012-07-04 |
넥타르 테라퓨틱스 |
Multi-arm polymer prodrugs
|
PE20050431A1
(en)
*
|
2003-09-22 |
2005-07-19 |
Boehringer Ingelheim Int |
MACROCYCLIC PEPTIDES ACTIVE AGAINST HEPATITIS C VIRUS
|
SG143252A1
(en)
|
2003-10-09 |
2008-06-27 |
Ambrx Inc |
Polymer derivatives
|
CA2542353A1
(en)
|
2003-10-10 |
2005-04-21 |
Xencor, Inc. |
Protein based tnf-alpha variants for the treatment of tnf-alpha related disorders
|
CA2542179A1
(en)
|
2003-10-10 |
2005-04-21 |
Novo Nordisk A/S |
Il-21 derivatives
|
EA011857B8
(en)
|
2003-10-14 |
2012-08-30 |
Интермьюн, Инк. |
Macrocyclic carboxylic acids and acylsulfonamides as inhibitors of hcv replication
|
ES2428358T3
(en)
|
2003-10-17 |
2013-11-07 |
Novo Nordisk A/S |
Combination therapy
|
US7407973B2
(en)
*
|
2003-10-24 |
2008-08-05 |
Intermune, Inc. |
Use of pirfenidone in therapeutic regimens
|
US7220407B2
(en)
*
|
2003-10-27 |
2007-05-22 |
Amgen Inc. |
G-CSF therapy as an adjunct to reperfusion therapy in the treatment of acute myocardial infarction
|
EP1725572B1
(en)
|
2003-11-05 |
2017-05-31 |
AGCT GmbH |
Macromolecular nucleotide compounds and methods for using the same
|
US8633157B2
(en)
|
2003-11-24 |
2014-01-21 |
Novo Nordisk A/S |
Glycopegylated erythropoietin
|
US20080305992A1
(en)
|
2003-11-24 |
2008-12-11 |
Neose Technologies, Inc. |
Glycopegylated erythropoietin
|
US20060040856A1
(en)
|
2003-12-03 |
2006-02-23 |
Neose Technologies, Inc. |
Glycopegylated factor IX
|
WO2005053730A1
(en)
*
|
2003-12-05 |
2005-06-16 |
Kirin Beer Kabushiki Kaisha |
Therapeutic agent for terminal heart failure
|
WO2005067963A1
(en)
*
|
2003-12-23 |
2005-07-28 |
Intermune, Inc. |
Use of polyethylene glycol-modified interferon-alpha in therapeutic dosing regimens
|
GB0500020D0
(en)
|
2005-01-04 |
2005-02-09 |
Novartis Ag |
Organic compounds
|
CA2552892C
(en)
|
2004-01-08 |
2014-08-05 |
Neose Technologies, Inc. |
O-linked glycosylation of peptides
|
DE602005025855D1
(en)
*
|
2004-01-21 |
2011-02-24 |
Boehringer Ingelheim Pharma |
MACROCYCLIC PEPTIDES WITH EFFECT TO THE HEPATITIS C VIRUS
|
NZ586034A
(en)
|
2004-02-02 |
2011-10-28 |
Ambrx Inc |
Modified human growth hormone polypeptides and their uses
|
CA2555894A1
(en)
*
|
2004-02-11 |
2005-08-25 |
Amylin Pharmaceuticals, Inc. |
Pancreatic polypeptide family motifs and polypeptides comprising the same
|
CA2849552A1
(en)
|
2004-02-11 |
2005-08-25 |
Amylin Pharmaceuticals, Llc |
Hybrid polypeptides with selectable properties
|
US8076288B2
(en)
|
2004-02-11 |
2011-12-13 |
Amylin Pharmaceuticals, Inc. |
Hybrid polypeptides having glucose lowering activity
|
US20090214472A1
(en)
*
|
2004-03-01 |
2009-08-27 |
Enzon Pharmaceuticals Inc. |
Interferon-beta polymer conjugates
|
JP2007530569A
(en)
*
|
2004-03-23 |
2007-11-01 |
アムジエン・インコーポレーテツド |
Chemically modified protein composition and method
|
US8470315B2
(en)
|
2004-04-13 |
2013-06-25 |
Quintessence Biosciences, Inc. |
Non-natural ribonuclease conjugates as cytotoxic agents
|
EP1586334A1
(en)
*
|
2004-04-15 |
2005-10-19 |
TRASTEC scpa |
G-CSF conjugates with peg
|
JP2008507298A
(en)
|
2004-05-19 |
2008-03-13 |
マキシジェン, インコーポレイテッド |
Interferon alpha polypeptides and conjugates
|
WO2005123113A2
(en)
*
|
2004-06-14 |
2005-12-29 |
Intermune, Inc. |
Interferon compositions and methods of use thereof
|
US7632924B2
(en)
|
2004-06-18 |
2009-12-15 |
Ambrx, Inc. |
Antigen-binding polypeptides and their uses
|
SG153865A1
(en)
|
2004-06-25 |
2009-07-29 |
Takeda Pharmaceutical |
Metastin derivatives and use thereof
|
JP2008509889A
(en)
*
|
2004-06-30 |
2008-04-03 |
イージェン コーポレーション |
PEGylated interferon alpha-1b
|
MX2007000216A
(en)
*
|
2004-07-08 |
2007-03-15 |
Amgen Inc |
Therapeutic peptides.
|
US20080300173A1
(en)
*
|
2004-07-13 |
2008-12-04 |
Defrees Shawn |
Branched Peg Remodeling and Glycosylation of Glucagon-Like Peptides-1 [Glp-1]
|
BRPI0512396A
(en)
|
2004-07-21 |
2008-03-11 |
Ambrx Inc |
biosynthetic polypeptides using non-naturally encoded amino acids
|
US7597884B2
(en)
|
2004-08-09 |
2009-10-06 |
Alios Biopharma, Inc. |
Hyperglycosylated polypeptide variants and methods of use
|
MX2007002029A
(en)
|
2004-08-19 |
2007-03-28 |
Biogen Idec Inc |
Neublastin variants.
|
CN101043899B
(en)
|
2004-08-19 |
2011-03-30 |
比奥根艾迪克Ma公司 |
Refolding transforming growth factor beta family proteins
|
EP1799249A2
(en)
|
2004-09-10 |
2007-06-27 |
Neose Technologies, Inc. |
Glycopegylated interferon alpha
|
US20060204512A1
(en)
|
2004-09-23 |
2006-09-14 |
Vasgene Therapeutics, Inc. |
Polypeptide compounds for inhibiting angiogenesis and tumor growth
|
US20080176790A1
(en)
|
2004-10-29 |
2008-07-24 |
Defrees Shawn |
Remodeling and Glycopegylation of Fibroblast Growth Factor (Fgf)
|
ATE544463T1
(en)
|
2004-11-05 |
2012-02-15 |
Univ Northwestern |
USE OF SCF AND G-SCF IN THE TREATMENT OF BRAIN SCHEMIA AND NEUROLOGICAL DISORDERS
|
EP3000826A1
(en)
|
2004-12-13 |
2016-03-30 |
Amylin Pharmaceuticals, LLC |
Pancreatic polypeptide family motifs, polypeptides and methods comprising the same
|
CA2594557C
(en)
|
2004-12-22 |
2016-04-26 |
Ambrx, Inc. |
Modified human growth hormone
|
JP2008525032A
(en)
|
2004-12-22 |
2008-07-17 |
アンブレツクス・インコーポレイテツド |
Methods for expressing and purifying recombinant human growth hormone
|
EP1674113A1
(en)
|
2004-12-22 |
2006-06-28 |
F. Hoffmann-La Roche Ag |
Conjugates of insulin-like growth factor-1 (IGF-1) and poly(ethylene glycol)
|
US7736872B2
(en)
|
2004-12-22 |
2010-06-15 |
Ambrx, Inc. |
Compositions of aminoacyl-TRNA synthetase and uses thereof
|
WO2006069246A2
(en)
|
2004-12-22 |
2006-06-29 |
Ambrx, Inc. |
Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides
|
KR101224781B1
(en)
|
2004-12-22 |
2013-01-21 |
암브룩스, 인코포레이티드 |
Formulations of human growth hormone comprising a non-naturally encoded amino acid
|
EP1858543B1
(en)
|
2005-01-10 |
2013-11-27 |
BioGeneriX AG |
Glycopegylated granulocyte colony stimulating factor
|
AU2006208199B2
(en)
|
2005-01-25 |
2012-06-07 |
Cell Therapeutics, Inc. |
Conjugates of biologically active proteins having a modified in vivo half-life
|
CA2596232A1
(en)
*
|
2005-01-31 |
2006-08-03 |
Effector Cell Institute |
The use of emip as cancer therapeutics in combination with electron beam irradiation or adjuvant treatment
|
US7402730B1
(en)
|
2005-02-03 |
2008-07-22 |
Lexicon Pharmaceuticals, Inc. |
Knockout animals manifesting hyperlipidemia
|
CA2597649A1
(en)
|
2005-02-11 |
2006-08-17 |
Amylin Pharmaceuticals, Inc. |
Gip analog and hybrid polypeptides with selectable properties
|
US8263545B2
(en)
*
|
2005-02-11 |
2012-09-11 |
Amylin Pharmaceuticals, Inc. |
GIP analog and hybrid polypeptides with selectable properties
|
WO2006094530A1
(en)
*
|
2005-03-11 |
2006-09-14 |
Siegfried Ltd. |
Di-polymer protein conjugates and processes for their preparation
|
WO2007010552A2
(en)
*
|
2005-03-17 |
2007-01-25 |
Serum Institute Of India Limited |
N- terminal peg conjugate of erythropoietin
|
ATE439140T1
(en)
|
2005-03-31 |
2009-08-15 |
Amylin Pharmaceuticals Inc |
AMYLIN AND AMYLIN AGONISTS FOR THE TREATMENT OF PSYCHIATRIC DISEASES AND DISORDERS
|
US20100092505A1
(en)
|
2005-04-05 |
2010-04-15 |
Elisabetta Bianchi |
Method for Shielding Functional Sites or Epitopes on Proteins
|
US9187546B2
(en)
|
2005-04-08 |
2015-11-17 |
Novo Nordisk A/S |
Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants
|
MX2007012547A
(en)
|
2005-04-11 |
2008-03-11 |
Savient Pharmaceuticals Inc |
Variant forms of urate oxidase and use thereof.
|
US7833979B2
(en)
|
2005-04-22 |
2010-11-16 |
Amgen Inc. |
Toxin peptide therapeutic agents
|
MX2007014524A
(en)
|
2005-05-18 |
2008-02-07 |
Maxygen Inc |
Evolved interferon-alpha polypeptides.
|
US20080255026A1
(en)
|
2005-05-25 |
2008-10-16 |
Glycopegylated Factor 1X |
Glycopegylated Factor Ix
|
DE602006020562D1
(en)
*
|
2005-06-01 |
2011-04-21 |
Maxygen Inc |
HREN FOR THIS
|
TW200722521A
(en)
*
|
2005-06-01 |
2007-06-16 |
Alza Corp |
Novel bioconjugation reactions for acylating polyethylene glycol reagents
|
WO2007009208A1
(en)
*
|
2005-06-02 |
2007-01-25 |
Cangene Corporation |
Poly(ethylene glocol) modified human gm-csf with increased biological activity
|
JP2008541769A
(en)
*
|
2005-06-03 |
2008-11-27 |
アンブレツクス・インコーポレイテツド |
Improved human interferon molecules and their use
|
KR100694994B1
(en)
*
|
2005-06-13 |
2007-03-14 |
씨제이 주식회사 |
Human Granulocyte-Colony Stimulating Factor Isoforms
|
US20090042790A1
(en)
*
|
2005-06-13 |
2009-02-12 |
Nastech Pharmaceutical Company Inc. |
Transmucosal delivery of peptide derivatives
|
JP2008546708A
(en)
|
2005-06-17 |
2008-12-25 |
ノバルティス アクチエンゲゼルシャフト |
Use of sanglifehrin in HCV
|
WO2006134173A2
(en)
|
2005-06-17 |
2006-12-21 |
Novo Nordisk Health Care Ag |
Selective reduction and derivatization of engineered proteins comprising at least one non-native cysteine
|
US7695710B2
(en)
*
|
2005-06-20 |
2010-04-13 |
Pepgen Corporation |
Antitumor and antiviral combination therapies using low-toxicity, long-circulating human interferon-alpha analogs
|
CN101257925A
(en)
*
|
2005-06-20 |
2008-09-03 |
派普根公司 |
Low-toxicity, long-circulating chimeras of human interferon-alpha analogs and interferon tau
|
EP2412744B1
(en)
|
2005-07-18 |
2014-01-22 |
Nektar Therapeutics |
Method for preparing branched functionalised polymers using branched polyol cores
|
KR100735784B1
(en)
|
2005-07-20 |
2007-07-06 |
재단법인 목암생명공학연구소 |
Mutant of granulocyte-colony stimulating factorG-CSF and chemically conjugated polypeptide thereof
|
AU2006276246B2
(en)
|
2005-07-25 |
2012-09-27 |
Intermune, Inc. |
Novel macrocyclic inhibitors of hepatitis C virus replication
|
WO2007015591A1
(en)
*
|
2005-08-02 |
2007-02-08 |
Cheil Industries Inc. |
Epoxy resin composition for packaging semiconductor device
|
CN101257926A
(en)
*
|
2005-08-04 |
2008-09-03 |
尼克塔治疗亚拉巴马公司 |
Conjugates of a G-CSF moiety and a polymer
|
EP2330125A3
(en)
|
2005-08-11 |
2012-12-12 |
Amylin Pharmaceuticals, Inc. |
Hybrid polypeptides with selectable properties
|
EP1922336B1
(en)
*
|
2005-08-11 |
2012-11-21 |
Amylin Pharmaceuticals, LLC |
Hybrid polypeptides with selectable properties
|
US8008453B2
(en)
|
2005-08-12 |
2011-08-30 |
Amgen Inc. |
Modified Fc molecules
|
JP4829969B2
(en)
|
2005-08-18 |
2011-12-07 |
アンブルックス,インコーポレイテッド |
tRNA compositions and uses thereof
|
EP1971362B1
(en)
|
2005-08-19 |
2014-12-03 |
Amylin Pharmaceuticals, LLC |
Exendin for treating diabetes and reducing body weight
|
US20070105755A1
(en)
|
2005-10-26 |
2007-05-10 |
Neose Technologies, Inc. |
One pot desialylation and glycopegylation of therapeutic peptides
|
UA93990C2
(en)
|
2005-10-11 |
2011-03-25 |
Интермюн, Инк. |
Compounds and methods for inhibiting hepatitis c viral replication
|
WO2007047303A2
(en)
*
|
2005-10-12 |
2007-04-26 |
Alvine Pharmaceuticals, Inc. |
Pegylated glutenase polypeptides
|
JP5905184B2
(en)
|
2005-10-13 |
2016-04-20 |
ヒューマン ジノーム サイエンシーズ, インコーポレイテッドHuman Genome Sciences, Inc. |
Methods and compositions for use in treating patients with autoantibody positive disease
|
US8168592B2
(en)
*
|
2005-10-21 |
2012-05-01 |
Amgen Inc. |
CGRP peptide antagonists and conjugates
|
JP2009514814A
(en)
*
|
2005-10-21 |
2009-04-09 |
シナジェバ・バイオファーマ・コーポレイション |
Glycosylated and glycosylated poultry-derived therapeutic proteins
|
US20080171696A1
(en)
*
|
2005-10-21 |
2008-07-17 |
Avigenics, Inc. |
Pharmacodynamically enhanced therapeutic proteins
|
US20090048440A1
(en)
|
2005-11-03 |
2009-02-19 |
Neose Technologies, Inc. |
Nucleotide Sugar Purification Using Membranes
|
WO2007056448A2
(en)
*
|
2005-11-08 |
2007-05-18 |
Ambrx, Inc. |
Accelerants for the modification of non-natural amino acids and non-natural amino acid polypeptides
|
PE20070684A1
(en)
|
2005-11-14 |
2007-08-06 |
Amgen Inc |
RANKL-PTH / PTHrP ANTIBODY CHEMERICAL MOLECULES
|
CN101454461A
(en)
*
|
2005-11-16 |
2009-06-10 |
Ambrx公司 |
Methods and compositions comprising non-natural amino acids
|
JP2009519942A
(en)
*
|
2005-12-14 |
2009-05-21 |
アンブルックス,インコーポレイテッド |
Compositions comprising unnatural amino acids and polypeptides, methods relating thereto, and uses thereof
|
US8404643B2
(en)
|
2005-12-22 |
2013-03-26 |
Takeda Pharmaceutical Company Limited |
Metastin derivatives and use thereof
|
CA2841386A1
(en)
|
2005-12-30 |
2007-07-12 |
Zensun (Shanghai) Science & Technology Limited |
Extended release of neuregulin for improved cardiac function
|
JP5046030B2
(en)
|
2006-01-12 |
2012-10-10 |
北里第一三共ワクチン株式会社 |
Oral composition containing interferon alpha
|
CN100475270C
(en)
*
|
2006-01-20 |
2009-04-08 |
清华大学 |
Medicine for treating tumor, and application thereof
|
US20070179094A1
(en)
|
2006-01-31 |
2007-08-02 |
Bayer Schering Pharma Ag |
Modulation of MDL-1 activity for treatment of inflammatory disease
|
US8309680B2
(en)
|
2006-02-21 |
2012-11-13 |
Nektar Therapeutics |
Segmented degradable polymers and conjugates made therefrom
|
TWI501774B
(en)
|
2006-02-27 |
2015-10-01 |
Biogen Idec Inc |
Treatments for neurological disorders
|
WO2007111661A2
(en)
|
2006-03-20 |
2007-10-04 |
Xoma Technology Ltd. |
Human antibodies specific for gastrin materials and methods
|
EP2007538A4
(en)
*
|
2006-03-31 |
2011-04-20 |
Centocor Ortho Biotech Inc |
Binding partners with immunoglobulin domains modified to have extended half-life
|
MX2008013119A
(en)
|
2006-04-11 |
2008-10-21 |
Novartis Ag |
Hcv/hiv inhibitors an their uses.
|
JO3324B1
(en)
|
2006-04-21 |
2019-03-13 |
Amgen Inc |
Lyophilized Therapeutic Peptibody Formulations
|
US8299024B2
(en)
*
|
2006-05-12 |
2012-10-30 |
Amylin Pharmaceuticals, Llc |
Methods to restore glycemic control
|
CA2652578A1
(en)
|
2006-05-19 |
2007-11-29 |
Glycofi, Inc. |
Erythropoietin compositions
|
RU2008145084A
(en)
|
2006-05-24 |
2010-06-27 |
Ново Нордиск Хелс Кеа Аг (Ch) |
ANALOGUES OF FACTOR IX HAVING A LONG-TERM HALF-TIME IN VIVO
|
US7981425B2
(en)
|
2006-06-19 |
2011-07-19 |
Amgen Inc. |
Thrombopoietic compounds
|
JP2009541333A
(en)
|
2006-06-23 |
2009-11-26 |
クインテセンス バイオサイエンシーズ インコーポレーティッド |
Modified ribonuclease
|
EP2452683A3
(en)
|
2006-06-26 |
2012-08-22 |
Amgen Inc. |
Methods for treating atherosclerosis
|
JP2009543868A
(en)
|
2006-07-17 |
2009-12-10 |
クインテセンス バイオサイエンシーズ インコーポレーティッド |
Methods and compositions for cancer treatment
|
CN101516388B
(en)
|
2006-07-21 |
2012-10-31 |
诺和诺德公司 |
Glycosylation of peptides via O-linked glycosylation sequences
|
DE602007006492D1
(en)
|
2006-07-25 |
2010-06-24 |
Lipoxen Technologies Ltd |
DERIVATISATION OF THE GRANULOCYTE COLONIESTIMULATING FACTOR
|
GB0615067D0
(en)
*
|
2006-07-28 |
2006-09-06 |
Ttp Communications Ltd |
Reconfigurable signal processing scheme
|
WO2008019214A1
(en)
*
|
2006-08-04 |
2008-02-14 |
Prolong Pharmaceuticals, Inc. |
Modified erythropoietin
|
ITMI20061624A1
(en)
*
|
2006-08-11 |
2008-02-12 |
Bioker Srl |
SINGLE-CONJUGATE SITE-SPECIFIC OF G-CSF
|
US8497240B2
(en)
|
2006-08-17 |
2013-07-30 |
Amylin Pharmaceuticals, Llc |
DPP-IV resistant GIP hybrid polypeptides with selectable properties
|
KR101106795B1
(en)
*
|
2006-08-31 |
2012-01-18 |
에프. 호프만-라 로슈 아게 |
Method for the production of insulin-like growth factor-i
|
CL2007002502A1
(en)
|
2006-08-31 |
2008-05-30 |
Hoffmann La Roche |
VARIANTS OF THE SIMILAR GROWTH FACTOR TO HUMAN INSULIN-1 (IGF-1) PEGILATED IN LISIN; METHOD OF PRODUCTION; FUSION PROTEIN THAT UNDERSTANDS IT; AND ITS USE TO TREAT ALZHEIMER'S DISEASE.
|
MX2009002526A
(en)
*
|
2006-09-08 |
2009-04-16 |
Ambrx Inc |
Suppressor trna transcription in vertebrate cells.
|
JP5840345B2
(en)
*
|
2006-09-08 |
2016-01-06 |
アンブルックス, インコーポレイテッドAmbrx, Inc. |
Modified human plasma polypeptides or modified human Fc scaffold proteins and uses thereof
|
DK2061878T3
(en)
*
|
2006-09-08 |
2014-04-07 |
Ambrx Inc |
HYBRID SUPPRESSOR TRNA FOR ANIMAL CELLS
|
US7985783B2
(en)
|
2006-09-21 |
2011-07-26 |
The Regents Of The University Of California |
Aldehyde tags, uses thereof in site-specific protein modification
|
ES2606034T3
(en)
|
2006-09-28 |
2017-03-17 |
Merck Sharp & Dohme Corp. |
Pegylated IL-10 for use in the treatment of lymphoma
|
US8969532B2
(en)
|
2006-10-03 |
2015-03-03 |
Novo Nordisk A/S |
Methods for the purification of polypeptide conjugates comprising polyalkylene oxide using hydrophobic interaction chromatography
|
CA2665480C
(en)
*
|
2006-10-04 |
2019-11-12 |
Shawn Defrees |
Glycerol linked pegylated sugars and glycopeptides
|
WO2008051383A2
(en)
*
|
2006-10-19 |
2008-05-02 |
Amgen Inc. |
Use of alcohol co-solvents to improve pegylation reaction yields
|
JO3048B1
(en)
|
2006-10-25 |
2016-09-05 |
Takeda Pharmaceuticals Co |
Metastin Derivatives And Use Thereof
|
AR063384A1
(en)
|
2006-10-25 |
2009-01-28 |
Amgen Inc |
THERAPEUTIC AGENTS BASED ON PEPTIDES DERIVED FROM TOXINS
|
KR101079993B1
(en)
*
|
2006-11-17 |
2011-11-04 |
동아제약주식회사 |
Polyethylene glycol-G-CSF conjugate
|
EP3156415A1
(en)
|
2006-11-22 |
2017-04-19 |
Bristol-Myers Squibb Company |
Targeted therapeutics based on engineered proteins for tyrosine kinases receptors, including igf-ir
|
DK2121751T3
(en)
|
2006-12-08 |
2017-04-24 |
Lexicon Pharmaceuticals Inc |
Monoclonal antibodies to ANGPTL3
|
ATE516814T1
(en)
|
2007-02-02 |
2011-08-15 |
Bristol Myers Squibb Co |
10FN3 DOMAIN FOR THE TREATMENT OF DISEASES ACCOMPANIED BY UNDESIRABLE ANGIOGENESIS
|
CN101245109B
(en)
*
|
2007-02-12 |
2011-12-14 |
杭州九源基因工程有限公司 |
Polyglycol single-modificatory recombined human granular leukocyte colony stimulating factor mutant and preparation method thereof
|
KR101476472B1
(en)
|
2007-03-30 |
2015-01-05 |
암브룩스, 인코포레이티드 |
Modified fgf-21 polypeptides and their uses
|
DK2144923T3
(en)
|
2007-04-03 |
2013-05-13 |
Biogenerix Ag |
METHODS OF TREATMENT WITH USING GLYCOPEGYLATED G-CSF
|
JP2008266219A
(en)
*
|
2007-04-20 |
2008-11-06 |
National Institute Of Advanced Industrial & Technology |
Protein not containing lysine and cysteine residues
|
TWI445544B
(en)
|
2007-05-01 |
2014-07-21 |
Biogen Idec Inc |
Compositions and methods for increasing vascularization
|
NZ580686A
(en)
|
2007-05-02 |
2012-11-30 |
Ambrx Inc |
Modified interferon beta polypeptides and their uses
|
EP2162540A2
(en)
|
2007-05-22 |
2010-03-17 |
Amgen Inc. |
Compositions and methods for producing bioactive fusion proteins
|
JP2010531135A
(en)
*
|
2007-06-04 |
2010-09-24 |
ノボ ノルディスク アクティーゼルスカブ |
O-linked glycosylation using N-acetylglucosaminyltransferase
|
ES2551123T3
(en)
|
2007-06-12 |
2015-11-16 |
Ratiopharm Gmbh |
Improved process for the production of nucleotide sugars
|
WO2009003188A2
(en)
*
|
2007-06-27 |
2008-12-31 |
Cedars-Sinai Medical Center |
N-terminal specific chemical labeling for proteomics applications
|
SI2489731T1
(en)
|
2007-07-26 |
2014-12-31 |
Amgen Inc. Patent Operations, M/S 28-2-C |
Modified lecithin-cholesterol acyltransferase enzymes
|
CN101352573B
(en)
*
|
2007-07-27 |
2011-02-09 |
杭州九源基因工程有限公司 |
Recombinant human granulocyte colony stimulating factor lysine defect body modified by polyethyleneglycol
|
EP2581441A1
(en)
|
2007-08-09 |
2013-04-17 |
Genzyme Corporation |
Method of treating autoimmune disease with mesenchymal stem cells
|
CL2008002399A1
(en)
*
|
2007-08-16 |
2009-01-02 |
Pharmaessentia Corp |
Substantially pure conjugate having a polymeric portion, a protein portion (interferon alpha 2b) and an aliphatic binder of 1 to 10 carbon atoms, useful in the treatment of hepatitis b or c.
|
SI2197919T1
(en)
|
2007-08-27 |
2014-09-30 |
Ratiopharm Gmbh |
Liquid formulation of g-csf conjugate
|
US8207112B2
(en)
|
2007-08-29 |
2012-06-26 |
Biogenerix Ag |
Liquid formulation of G-CSF conjugate
|
WO2009046015A2
(en)
*
|
2007-09-30 |
2009-04-09 |
University Of Florida Research Foundation, Inc. |
Combination therapies for treating type 1 diabetes
|
EP2205271B1
(en)
*
|
2007-10-08 |
2014-05-21 |
Quintessence Biosciences, Inc. |
Compositions and methods for ribonuclease-based therapies
|
CN101835496B
(en)
*
|
2007-10-23 |
2015-11-25 |
尼克塔治疗公司 |
The multiarm polymers of hydroxyapatite-targeting and the conjugate by its manufacture
|
AU2008326324B9
(en)
*
|
2007-11-20 |
2012-11-15 |
Ambrx, Inc. |
Modified insulin polypeptides and their uses
|
US20110124841A1
(en)
*
|
2007-12-13 |
2011-05-26 |
Monthony James F |
Polypeptides Modified by Protein Trans-Splicing Technology
|
DK2245456T3
(en)
*
|
2007-12-27 |
2013-03-04 |
Baxter Int |
Methods and compositions for the specific detection of physiologically acceptable polymer molecules
|
WO2009120396A2
(en)
*
|
2008-01-08 |
2009-10-01 |
The University Of California |
Compositions and methods for regulating erythropoientin expression and ameliorating anemia and stimulating erythropoiesis
|
JP5647899B2
(en)
*
|
2008-01-08 |
2015-01-07 |
ラツィオファルム ゲーエムベーハーratiopharm GmbH |
Glycoconjugation of polypeptides using oligosaccharyltransferase
|
US20090183503A1
(en)
*
|
2008-01-18 |
2009-07-23 |
Alberto Verdesi |
Exhaust apparatus
|
CN105274072A
(en)
|
2008-01-18 |
2016-01-27 |
生物马林药物股份有限公司 |
Manufacture of active highly phosphorylated human lysosomal sulfatase enzymes and uses thereof
|
US9938333B2
(en)
|
2008-02-08 |
2018-04-10 |
Ambrx, Inc. |
Modified leptin polypeptides and their uses
|
US8629104B2
(en)
|
2008-02-18 |
2014-01-14 |
Jiangsu Hengrui Medicine Co. Ltd. |
G-CSF and water-soluble polymer conjugate
|
CN101965200B
(en)
|
2008-02-27 |
2013-06-19 |
诺沃-诺迪斯克有限公司 |
Conjugated factor VIII molecules
|
TWI395593B
(en)
|
2008-03-06 |
2013-05-11 |
Halozyme Inc |
In vivo temporal control of activatable matrix-degrading enzymes
|
WO2009121210A1
(en)
|
2008-04-03 |
2009-10-08 |
厦门伯赛基因转录技术有限公司 |
Double-stranded polyethylene glycol modified growth hormone, preparation method and application thereof
|
CN101965516A
(en)
*
|
2008-04-03 |
2011-02-02 |
弗·哈夫曼-拉罗切有限公司 |
Pegylated insulin-like-growth-factor assay
|
KR101647932B1
(en)
|
2008-04-14 |
2016-08-11 |
할로자임, 아이엔씨 |
Modified hyaluronidases and uses in treating hyaluronan-associated diseases and conditions
|
TWI394580B
(en)
|
2008-04-28 |
2013-05-01 |
Halozyme Inc |
Super fast-acting insulin compositions
|
WO2009143285A2
(en)
|
2008-05-21 |
2009-11-26 |
Amylin Pharmaceuticals, Inc. |
Exendins to lower cholestrol and triglycerides
|
JP2011520961A
(en)
|
2008-05-22 |
2011-07-21 |
ブリストル−マイヤーズ スクイブ カンパニー |
Scaffold domain protein based on multivalent fibronectin
|
JOP20190083A1
(en)
|
2008-06-04 |
2017-06-16 |
Amgen Inc |
Fgf21 mutant fusion polypeptides and uses thereof
|
GB0811743D0
(en)
|
2008-06-26 |
2008-07-30 |
Hemosol Biopharma Inc |
Composition
|
CA2729012A1
(en)
|
2008-06-27 |
2009-12-30 |
Amgen Inc. |
Ang-2 inhibition to treat multiple sclerosis
|
ES2963062T3
(en)
*
|
2008-07-23 |
2024-03-25 |
Ambrx Inc |
Modified bovine G-CSF polypeptides and their uses
|
EP2314609B1
(en)
*
|
2008-07-30 |
2016-11-30 |
Takeda Pharmaceutical Company Limited |
Metastin derivative and use thereof
|
CN102131844B
(en)
*
|
2008-07-31 |
2016-03-02 |
药华医药股份有限公司 |
Peptide-polymer conjugates
|
CA2732508C
(en)
|
2008-08-11 |
2016-03-15 |
Nektar Therapeutics |
Multi-arm polymeric alkanoate conjugates
|
WO2010030366A2
(en)
|
2008-09-11 |
2010-03-18 |
Nektar Therapeutics |
Polymeric alpha-hydroxy aldehyde and ketone reagents and conjugation method
|
NZ592249A
(en)
|
2008-09-26 |
2013-03-28 |
Ambrx Inc |
Non-natural amino acid replication-dependent microorganisms and vaccines
|
BRPI0919403A2
(en)
|
2008-09-26 |
2017-09-26 |
Ambrx Inc |
modified animal erythropoietin polypeptides and their uses
|
EP2334695B1
(en)
|
2008-10-01 |
2015-12-23 |
Quintessence Biosciences, Inc. |
Therapeutic ribonucleases
|
MX341149B
(en)
|
2008-10-10 |
2016-08-09 |
Amgen Inc |
Fgf21 mutants and uses thereof.
|
JP4966434B2
(en)
|
2008-10-15 |
2012-07-04 |
バクスター・インターナショナル・インコーポレイテッド |
PEGylation of recombinant blood clotting factors in the presence of conjugated antibodies
|
SI2349342T1
(en)
*
|
2008-10-17 |
2018-10-30 |
Baxalta GmbH |
Modified blood factors comprising a low degree of water soluble polymer
|
BRPI0919827B8
(en)
*
|
2008-10-20 |
2021-05-25 |
Usv Ltd |
processes for increasing the yield of an r-methug-csf pegylation reaction process for gram scale production of peg- r-methug-csf
|
JP5775820B2
(en)
*
|
2008-10-21 |
2015-09-09 |
バクスター・インターナショナル・インコーポレイテッドBaxter International Incorp0Rated |
Method for determining active ingredient (in vitro dePEGylation) in a prodrug PEG protein conjugate with a releasable PEG reagent
|
AU2009308909A1
(en)
*
|
2008-10-31 |
2010-05-06 |
Amgen Inc. |
Materials and methods relating to stem cell mobilization by multi-PEGylated granulocyte colony stimulating factor
|
IT1392655B1
(en)
|
2008-11-20 |
2012-03-16 |
Bio Ker S R L |
SITE-SPECIFIC MONOCONJUGATED INSULINOTROPIC GLP-1 PEPTIDES.
|
TWI496582B
(en)
|
2008-11-24 |
2015-08-21 |
必治妥美雅史谷比公司 |
Bispecific egfr/igfir binding molecules
|
PT3037529T
(en)
|
2008-12-09 |
2019-05-31 |
Halozyme Inc |
Extended soluble ph20 polypeptides and uses thereof
|
US20100152115A1
(en)
*
|
2008-12-11 |
2010-06-17 |
Baxter International Inc. |
Detection of physiologically acceptable polymer molecules using near infrared spectroscopy
|
CN103601800B
(en)
|
2008-12-17 |
2015-10-21 |
默沙东公司 |
The production of single and double PEG IL10 and purposes
|
US20110182850A1
(en)
|
2009-04-10 |
2011-07-28 |
Trixi Brandl |
Organic compounds and their uses
|
US8512690B2
(en)
|
2009-04-10 |
2013-08-20 |
Novartis Ag |
Derivatised proline containing peptide compounds as protease inhibitors
|
AU2010246038A1
(en)
|
2009-05-05 |
2011-12-01 |
Amgen Inc. |
FGF21 mutants and uses thereof
|
SI3248610T1
(en)
|
2009-05-05 |
2024-03-29 |
Amgen Inc., |
Fgf21 mutants and uses thereof
|
EP3175863B1
(en)
|
2009-05-20 |
2021-12-01 |
BioMarin Pharmaceutical Inc. |
Variants of c-type natriuretic peptide
|
WO2010148142A1
(en)
|
2009-06-17 |
2010-12-23 |
Amgen Inc. |
Chimeric fgf19 polypeptides and uses thereof
|
RU2012101779A
(en)
|
2009-06-19 |
2013-07-27 |
МЕДИММЬЮН, ЭлЭлСи |
PROSTHETIC OPTIONS
|
WO2010151823A1
(en)
|
2009-06-25 |
2010-12-29 |
Savient Pharmaceuticals Inc. |
Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response by monitoring serum uric acid during pegylated uricase therapy
|
US20110027229A1
(en)
|
2009-07-31 |
2011-02-03 |
Medtronic, Inc. |
Continuous subcutaneous administration of interferon-alpha to hepatitis c infected patients
|
DK2477603T3
(en)
|
2009-09-17 |
2016-06-13 |
Baxalta Inc |
STABLE CO-DEVELOPMENT OF hyaluronidase and Immunoglobulin, AND METHODS OF USE THEREOF
|
JP5885664B2
(en)
|
2009-09-25 |
2016-03-15 |
ゾーマ テクノロジー リミテッド |
Screening method
|
CA2775287A1
(en)
*
|
2009-09-25 |
2011-03-31 |
Vybion, Inc. |
Polypeptide modification
|
US8926976B2
(en)
|
2009-09-25 |
2015-01-06 |
Xoma Technology Ltd. |
Modulators
|
US9315860B2
(en)
|
2009-10-26 |
2016-04-19 |
Genovoxx Gmbh |
Conjugates of nucleotides and method for the application thereof
|
AU2010313456A1
(en)
|
2009-10-30 |
2012-05-17 |
Ntf Therapeutics, Inc. |
Improved neurturin molecules
|
BR112012010110A2
(en)
|
2009-10-30 |
2019-09-24 |
Boehringer Ingelheim Int |
hcv combination therapy dosage regimens comprising bi201335, interferon alfa and ribavirin
|
KR20120116942A
(en)
|
2009-11-23 |
2012-10-23 |
아밀린 파마슈티칼스, 인크. |
Polypeptide conjugate
|
KR20120123299A
(en)
|
2009-12-04 |
2012-11-08 |
제넨테크, 인크. |
Multispecific antibodies, antibody analogs, compositions, and methods
|
UA109888C2
(en)
|
2009-12-07 |
2015-10-26 |
|
ANTIBODY OR ANTIBODILITY ANTIBODY OR ITS BINDING TO THE β-CLOTE, FGF RECEPTORS AND THEIR COMPLEXES
|
CN107674121A
(en)
|
2009-12-21 |
2018-02-09 |
Ambrx 公司 |
Bovine somatotropin polypeptide and its purposes by modification
|
CN104017063A
(en)
|
2009-12-21 |
2014-09-03 |
Ambrx公司 |
Modified porcine somatotropin polypeptides and their uses
|
US20110152188A1
(en)
*
|
2009-12-23 |
2011-06-23 |
Hanns-Christian Mahler |
Pharmaceutical compositions of igf/i proteins
|
WO2011101242A1
(en)
|
2010-02-16 |
2011-08-25 |
Novo Nordisk A/S |
Factor viii molecules with reduced vwf binding
|
JP5840148B2
(en)
|
2010-03-04 |
2016-01-06 |
フェニックス インク. |
Method for producing soluble recombinant interferon protein without denaturation
|
EP2552949B1
(en)
|
2010-04-01 |
2016-08-17 |
Pfenex Inc. |
Methods for g-csf production in a pseudomonas host cell
|
WO2011130417A2
(en)
|
2010-04-15 |
2011-10-20 |
Amgen Inc. |
HUMAN FGF RECEPTOR AND β-KLOTHO BINDING PROTEINS
|
EP2563380B1
(en)
|
2010-04-26 |
2018-05-30 |
aTyr Pharma, Inc. |
Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of cysteinyl-trna synthetase
|
AU2011248614B2
(en)
|
2010-04-27 |
2017-02-16 |
Pangu Biopharma Limited |
Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of isoleucyl tRNA synthetases
|
US8993723B2
(en)
|
2010-04-28 |
2015-03-31 |
Atyr Pharma, Inc. |
Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of alanyl-tRNA synthetases
|
EP2563383B1
(en)
|
2010-04-29 |
2017-03-01 |
Atyr Pharma, Inc. |
Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of valyl trna synthetases
|
CA2797374C
(en)
|
2010-04-29 |
2021-02-16 |
Pangu Biopharma Limited |
Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of asparaginyl trna synthetases
|
CN102234310B
(en)
*
|
2010-04-30 |
2017-02-08 |
杭州九源基因工程有限公司 |
Polyethylene glycol modified protein separating and purifying method
|
ES2623805T3
(en)
|
2010-05-03 |
2017-07-12 |
Atyr Pharma, Inc. |
Innovative discovery of therapeutic, diagnostic and antibody compositions related to phenylalanyl-alpha-tRNA synthetase protein fragments
|
WO2011139986A2
(en)
|
2010-05-03 |
2011-11-10 |
Atyr Pharma, Inc. |
Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of arginyl-trna synthetases
|
CN103140233B
(en)
|
2010-05-03 |
2017-04-05 |
Atyr 医药公司 |
Treatment, diagnosis and the discovery of antibody compositions related to the protein fragments of methionyl-tRNA synthetase
|
JP6008844B2
(en)
|
2010-05-04 |
2016-10-19 |
エータイアー ファーマ, インコーポレイテッド |
Innovative discovery of therapeutic, diagnostic and antibody compositions related to protein fragments of the p38 MULTI-tRNA synthetase complex
|
JP2013528374A
(en)
|
2010-05-10 |
2013-07-11 |
パーシード セラピューティクス リミテッド ライアビリティ カンパニー |
Polypeptide inhibitors of VLA4
|
AU2011252990B2
(en)
|
2010-05-14 |
2017-04-20 |
Pangu Biopharma Limited |
Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of phenylalanyl-beta-tRNA synthetases
|
JP2013533217A
(en)
|
2010-05-17 |
2013-08-22 |
セビックス・インコーポレイテッド |
PEGylated C-peptide
|
CA2799480C
(en)
|
2010-05-17 |
2020-12-15 |
Atyr Pharma, Inc. |
Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of leucyl-trna synthetases
|
CN103180339B
(en)
|
2010-05-26 |
2016-04-27 |
百时美施贵宝公司 |
There is the scaffold protein based on fibronectin of the stability of improvement
|
EP2575856B1
(en)
|
2010-05-27 |
2017-08-16 |
aTyr Pharma, Inc. |
Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glutaminyl-trna synthetases
|
WO2011153277A2
(en)
|
2010-06-01 |
2011-12-08 |
Atyr Pharma, Inc. |
Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of lysyl-trna synthetases
|
US20120123338A1
(en)
|
2010-06-16 |
2012-05-17 |
Medtronic, Inc. |
Damping systems for stabilizing medications in drug delivery devices
|
JP2013529627A
(en)
|
2010-06-24 |
2013-07-22 |
パンメド リミテッド |
Treatment of hepatitis C virus-related disease using hydroxychloroquine or a combination of hydroxychloroquine and an antiviral agent
|
WO2012021247A2
(en)
|
2010-07-12 |
2012-02-16 |
Atyr Pharma, Inc. |
Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glycyl-trna synthetases
|
JP2013532176A
(en)
|
2010-07-15 |
2013-08-15 |
ノヴォ ノルディスク アー/エス |
Stabilized factor VIII variant
|
ES2661089T3
(en)
|
2010-07-20 |
2018-03-27 |
Halozyme Inc. |
Methods of treatment or prevention of adverse side effects associated with the administration of an anti-hyaluronan agent
|
AR082319A1
(en)
|
2010-07-22 |
2012-11-28 |
Biomarin Pharm Inc |
PRODUCTION OF A HIGHLY ACTIVE PHOSPHORILED HUMAN N-ACETILGALACTOSAMINE-6-SULPHATASE AND ITS USES
|
EP3578205A1
(en)
|
2010-08-06 |
2019-12-11 |
ModernaTX, Inc. |
A pharmaceutical formulation comprising engineered nucleic acids and medical use thereof
|
RU2446173C1
(en)
*
|
2010-08-13 |
2012-03-27 |
Зао "Биокад" |
New functional, high-purity stable conjugate of granulocyte colony-stimulating factor (g-csf) and polyethylene glycol with prolonged biological action, applicable for medical purposes, and based immunobiological agent
|
US9567386B2
(en)
|
2010-08-17 |
2017-02-14 |
Ambrx, Inc. |
Therapeutic uses of modified relaxin polypeptides
|
EP2605789B1
(en)
|
2010-08-17 |
2019-06-05 |
Ambrx, Inc. |
Modified relaxin polypeptides and their uses
|
AU2011293294B2
(en)
|
2010-08-25 |
2016-03-24 |
Pangu Biopharma Limited |
Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of Tyrosyl-tRNA synthetases
|
WO2012035050A2
(en)
|
2010-09-15 |
2012-03-22 |
Novo Nordisk A/S |
Factor viii variants having a decreased cellular uptake
|
AR083006A1
(en)
|
2010-09-23 |
2013-01-23 |
Lilly Co Eli |
FORMULATIONS FOR THE STIMULATING FACTOR OF COLONIES OF GRANULOCITS (G-CSF) BOVINE AND VARIANTS OF THE SAME
|
DK3241558T3
(en)
|
2010-09-28 |
2021-04-26 |
Aegerion Pharmaceuticals Inc |
HIGH RESOLUTION LEPTINES
|
CA2811700A1
(en)
|
2010-10-05 |
2012-04-12 |
Novartis Ag |
New treatments of hepatitis c virus infection
|
US9011833B2
(en)
|
2010-10-08 |
2015-04-21 |
Novartis Ag |
Vitamin E formulations of sulfamide NS3 inhibitors
|
CN102453089B
(en)
*
|
2010-10-25 |
2014-06-04 |
北京凯因科技股份有限公司 |
Preparation and application of recombinant consensus interferon mutant polyethylene glycol conjugate
|
CN103933577B
(en)
*
|
2010-10-25 |
2014-12-10 |
北京凯因科技股份有限公司 |
Preparation and application of recombinant interferon variant polyethylene glycol conjugate
|
US9023791B2
(en)
|
2010-11-19 |
2015-05-05 |
Novartis Ag |
Fibroblast growth factor 21 mutations
|
MX357166B
(en)
|
2010-11-24 |
2018-06-28 |
Lexicon Pharmaceuticals Inc |
Antibodies to notum pectinacetylesterase.
|
CN103221053A
(en)
|
2010-11-30 |
2013-07-24 |
诺华有限公司 |
New treatments of hepatitis c virus infection
|
CN102485742A
(en)
*
|
2010-12-02 |
2012-06-06 |
山东新时代药业有限公司 |
Preparation method and separation and purification method of polyethylene glycol single modified recombinant human granulocyte-colony stimulating factor
|
US20140371258A1
(en)
|
2010-12-17 |
2014-12-18 |
Nektar Therapeutics |
Water-Soluble Polymer Conjugates of Topotecan
|
JP5899241B2
(en)
|
2010-12-21 |
2016-04-06 |
ネクター セラピューティクス |
Multi-arm polymer prodrug conjugates of pemetrexed-based compounds
|
WO2012088422A1
(en)
|
2010-12-22 |
2012-06-28 |
Nektar Therapeutics |
Multi-arm polymeric prodrug conjugates of taxane-based compounds
|
US10894087B2
(en)
|
2010-12-22 |
2021-01-19 |
Nektar Therapeutics |
Multi-arm polymeric prodrug conjugates of cabazitaxel-based compounds
|
WO2012109387A1
(en)
|
2011-02-08 |
2012-08-16 |
Halozyme, Inc. |
Composition and lipid formulation of a hyaluronan-degrading enzyme and the use thereof for treatment of benign prostatic hyperplasia
|
EP2686340A2
(en)
|
2011-03-16 |
2014-01-22 |
Amgen Inc. |
Potent and selective inhibitors of nav1.3 and nav1.7
|
WO2012135046A1
(en)
*
|
2011-03-25 |
2012-10-04 |
The Trustees Of Columbia University In The City Of New York |
Pegylated human hdl particle and process for production thereof
|
KR20140007927A
(en)
|
2011-03-31 |
2014-01-20 |
노파르티스 아게 |
Alisporivir to treat hepatitis c virus infection
|
PL2694087T3
(en)
|
2011-04-01 |
2015-06-30 |
Novartis Ag |
Treatment for infection with hepatitis b virus alone or in combination with hepatitis delta virus and associated liver diseases
|
US20150104415A1
(en)
|
2011-04-13 |
2015-04-16 |
Debiopharm International Sa |
Treatments of Hepatitis C virus infection
|
EP2709669A1
(en)
|
2011-05-17 |
2014-03-26 |
Bristol-Myers Squibb Company |
Methods for maintaining pegylation of polypeptides
|
SI2714735T1
(en)
|
2011-06-03 |
2021-12-31 |
Xoma Technology Ltd. |
Antibodies specific for tgf-beta
|
WO2012174480A2
(en)
|
2011-06-17 |
2012-12-20 |
Halozyme, Inc. |
Continuous subcutaneous insulin infusion methods with a hyaluronan degrading enzyme
|
US20130011378A1
(en)
|
2011-06-17 |
2013-01-10 |
Tzung-Horng Yang |
Stable formulations of a hyaluronan-degrading enzyme
|
US20130090294A1
(en)
|
2011-06-28 |
2013-04-11 |
Alternative Innovative Technologies Llc |
Novel methods of use of hsp70 for increased performance or treatment of hsp70 related disorders
|
AU2012280474A1
(en)
|
2011-07-01 |
2014-01-16 |
Bayer Intellectual Property Gmbh |
Relaxin fusion polypeptides and uses thereof
|
CA2840221A1
(en)
|
2011-07-05 |
2013-01-10 |
Bioasis Technologies Inc. |
P97-antibody conjugates and methods of use
|
US20140256621A1
(en)
|
2011-07-08 |
2014-09-11 |
Astrazeneca Pharmaceuticals Lp |
Engineered poypeptides having enhanced duration of action and reduced immunogenicity
|
CN102952067A
(en)
*
|
2011-08-30 |
2013-03-06 |
苏州欣诺科生物科技有限公司 |
Pyridoxal derivative for pegylation modification of N terminal of protein and preparation method and application thereof
|
AU2012301769B2
(en)
|
2011-08-31 |
2016-05-19 |
Amgen Inc. |
FGF21 for use in treating type 1 diabetes
|
WO2013040501A1
(en)
|
2011-09-16 |
2013-03-21 |
Pharmathene, Inc. |
Compositions and combinations of organophosphorus bioscavengers and hyaluronan-degrading enzymes, and uses thereof
|
TWI593708B
(en)
|
2011-09-26 |
2017-08-01 |
諾華公司 |
Fusion proteins for treating metabolic disorders
|
UY34347A
(en)
|
2011-09-26 |
2013-04-30 |
Novartis Ag |
DUAL FUNCTION PROTEINS TO TREAT METABOLIC DISORDERS
|
EP2760461A1
(en)
|
2011-09-27 |
2014-08-06 |
Novartis AG |
Alisporivr for treatment of hepatis c virus infection
|
RU2014114849A
(en)
|
2011-10-14 |
2015-11-20 |
Алтернатив Инновейтив Текнолоджиз Ллц |
Degradation-resistant derivatives of proteins of heat shock-70 (btsh70) and methods of their application (options)
|
BR112014009797A2
(en)
|
2011-10-24 |
2020-10-27 |
Halozyme, Inc. |
Company diagnosis for anti-hyaluronan agent therapy and methods of its use
|
EP2771300B1
(en)
|
2011-10-25 |
2017-12-20 |
Corning Incorporated |
Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
|
US10350139B2
(en)
|
2011-10-25 |
2019-07-16 |
Corning Incorporated |
Pharmaceutical glass packaging assuring pharmaceutical sterility
|
JP2015504038A
(en)
|
2011-10-31 |
2015-02-05 |
ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company |
Fibronectin binding domain with reduced immunogenicity
|
CA2855770A1
(en)
|
2011-11-17 |
2013-05-23 |
Cebix Ab |
Pegylated c-peptide
|
RU2685867C2
(en)
|
2011-12-15 |
2019-04-23 |
Алтернатив Инновейтив Текнолоджиз Ллц |
Hybrid proteins and protein conjugates based on heat shock protein-70 (hsp70) and methods for use thereof (versions)
|
PT3130347T
(en)
|
2011-12-30 |
2019-12-10 |
Halozyme Inc |
Ph20 polypeptide variants, formulations and uses thereof
|
JP2015506369A
(en)
|
2012-01-30 |
2015-03-02 |
アレコー リミテッド |
Stabilized aqueous antibody composition
|
EP2814514B1
(en)
|
2012-02-16 |
2017-09-13 |
Atyr Pharma, Inc. |
Histidyl-trna synthetases for treating autoimmune and inflammatory diseases
|
MX366864B
(en)
|
2012-02-27 |
2019-07-26 |
Amunix Operating Inc |
Xten conjugate compositions and methods of making same.
|
US20150030564A1
(en)
|
2012-02-29 |
2015-01-29 |
Toray Industries, Inc. |
Inhibitory agent for body cavity fluid accumulation
|
EP2822575B1
(en)
|
2012-03-03 |
2020-05-06 |
ImmunGene, Inc. |
Engineered antibody-interferon mutant fusion molecules
|
WO2013137869A1
(en)
|
2012-03-14 |
2013-09-19 |
Boehringer Ingelheim International Gmbh |
Combination therapy for treating hcv infection in an hcv-hiv coinfected patient population
|
WO2013143581A1
(en)
|
2012-03-28 |
2013-10-03 |
Boehringer Ingelheim International Gmbh |
Combination therapy for treating hcv infection in specific patient subgenotype sub-population
|
WO2013149219A2
(en)
|
2012-03-30 |
2013-10-03 |
Sorrento Therapeutics Inc. |
Fully human antibodies that bind to vegfr2
|
CA2986512C
(en)
|
2012-04-04 |
2022-05-17 |
Halozyme, Inc. |
Combination therapy with an anti-hyaluronan agent and a tumor-targeted taxane
|
CN115093480A
(en)
|
2012-05-31 |
2022-09-23 |
索伦托药业有限公司 |
Antigen binding proteins that bind to PD-L1
|
US9738724B2
(en)
|
2012-06-08 |
2017-08-22 |
Sutro Biopharma, Inc. |
Antibodies comprising site-specific non-natural amino acid residues, methods of their preparation and methods of their use
|
JP6438391B2
(en)
|
2012-06-22 |
2018-12-12 |
ソレント・セラピューティクス・インコーポレイテッドSorrento Therapeutics, Inc. |
Antigen binding protein that binds to CCR2
|
EP2863955B1
(en)
|
2012-06-26 |
2016-11-23 |
Sutro Biopharma, Inc. |
Modified fc proteins comprising site-specific non-natural amino acid residues, conjugates of the same, methods of their preparation and methods of their use
|
US9932565B2
(en)
|
2012-07-31 |
2018-04-03 |
Bioasis Technologies, Inc. |
Dephosphorylated lysosomal storage disease proteins and methods of use thereof
|
SI3584255T1
(en)
|
2012-08-31 |
2022-05-31 |
Sutro Biopharma, Inc |
Modified amino acids comprising an azido group
|
US9278124B2
(en)
|
2012-10-16 |
2016-03-08 |
Halozyme, Inc. |
Hypoxia and hyaluronan and markers thereof for diagnosis and monitoring of diseases and conditions and related methods
|
EP2916835A4
(en)
|
2012-11-12 |
2016-07-27 |
Redwood Bioscience Inc |
Compounds and methods for producing a conjugate
|
US9310374B2
(en)
|
2012-11-16 |
2016-04-12 |
Redwood Bioscience, Inc. |
Hydrazinyl-indole compounds and methods for producing a conjugate
|
KR20150085064A
(en)
|
2012-11-16 |
2015-07-22 |
더 리젠트스 오브 더 유니이버시티 오브 캘리포니아 |
Pictet-spengler ligation for protein chemical modification
|
US20140205566A1
(en)
|
2012-11-30 |
2014-07-24 |
Novartis Ag |
Cyclic nucleuoside derivatives and uses thereof
|
US9383357B2
(en)
|
2012-12-07 |
2016-07-05 |
Northwestern University |
Biomarker for replicative senescence
|
EP2935311B1
(en)
|
2012-12-20 |
2021-03-31 |
Amgen Inc. |
Apj receptor agonists and uses thereof
|
CN103908660B
(en)
*
|
2013-01-05 |
2015-02-04 |
石药集团百克(山东)生物制药有限公司 |
Polyethylene glycol modified rhG-CSF pharmaceutical composition and preparation method thereof
|
US20150361159A1
(en)
|
2013-02-01 |
2015-12-17 |
Bristol-Myers Squibb Company |
Fibronectin based scaffold proteins
|
CN103113466B
(en)
*
|
2013-03-01 |
2015-06-03 |
中国科学院过程工程研究所 |
Recombinant human interferon beta-1b modified by polyethylene glycol and preparation method of recombinant human interferon beta-1b
|
US10344060B2
(en)
|
2013-03-12 |
2019-07-09 |
Amgen Inc. |
Potent and selective inhibitors of Nav1.7
|
AU2014243816B2
(en)
|
2013-03-13 |
2019-01-31 |
Bioasis Technologies Inc. |
Fragments of p97 and uses thereof
|
RU2535002C2
(en)
*
|
2013-04-04 |
2014-12-10 |
Федеральное государственное бюджетное учреждение "Научно-исследовательский институт фармакологии" Сибирского отделения Российской академии медицинских наук |
Method for correction of remote consequences of spermatogenesis caused by cytostatic exposure
|
CN105209054A
(en)
|
2013-04-18 |
2015-12-30 |
阿尔莫生物科技股份有限公司 |
Methods of using interleukin-10 for treating diseases and disorders
|
US9707153B2
(en)
|
2013-04-24 |
2017-07-18 |
Corning Incorporated |
Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
|
US9717648B2
(en)
|
2013-04-24 |
2017-08-01 |
Corning Incorporated |
Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
|
US9717649B2
(en)
|
2013-04-24 |
2017-08-01 |
Corning Incorporated |
Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
|
US9849066B2
(en)
|
2013-04-24 |
2017-12-26 |
Corning Incorporated |
Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
|
US9707154B2
(en)
|
2013-04-24 |
2017-07-18 |
Corning Incorporated |
Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
|
US9707155B2
(en)
|
2013-04-24 |
2017-07-18 |
Corning Incorporated |
Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
|
US9713572B2
(en)
|
2013-04-24 |
2017-07-25 |
Corning Incorporated |
Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
|
US9700485B2
(en)
|
2013-04-24 |
2017-07-11 |
Corning Incorporated |
Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
|
US9603775B2
(en)
|
2013-04-24 |
2017-03-28 |
Corning Incorporated |
Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
|
US9839579B2
(en)
|
2013-04-24 |
2017-12-12 |
Corning Incorporated |
Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
|
US9700486B2
(en)
|
2013-04-24 |
2017-07-11 |
Corning Incorporated |
Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
|
US9823255B2
(en)
|
2013-06-17 |
2017-11-21 |
Armo Biosciences, Inc. |
Method for assessing protein identity and stability
|
TW201534726A
(en)
|
2013-07-03 |
2015-09-16 |
Halozyme Inc |
Thermally stable PH20 hyaluronidase variants and uses thereof
|
ES2658039T3
(en)
|
2013-07-10 |
2018-03-08 |
Sutro Biopharma, Inc. |
Antibodies comprising multiple site-specific non-natural amino acid residues, methods for their preparation and methods of use
|
AU2014312190A1
(en)
|
2013-08-28 |
2016-02-18 |
Bioasis Technologies Inc. |
CNS-targeted conjugates of antibodies
|
WO2015031316A1
(en)
|
2013-08-30 |
2015-03-05 |
Armo Biosciences, Inc. |
Methods of using interleukin-10 for treating diseases and disorders
|
CN105792839A
(en)
|
2013-10-02 |
2016-07-20 |
诺华股份有限公司 |
Insulin-like growth factor mimetics for use in therapy
|
WO2015054658A1
(en)
|
2013-10-11 |
2015-04-16 |
Sutro Biopharma, Inc. |
Modified amino acids comprising tetrazine functional groups, methods of preparation, and methods of their use
|
EP3057605A1
(en)
|
2013-10-18 |
2016-08-24 |
Novartis AG |
Methods of treating diabetes and related disorders
|
KR20160079114A
(en)
|
2013-11-11 |
2016-07-05 |
아르모 바이오사이언시스 인코포레이티드 |
Methods of using interleukin-10 for treating diseases and disorders
|
US20160296632A1
(en)
|
2013-11-13 |
2016-10-13 |
Aequus Biopharma, Inc. |
Engineered glycoproteins and uses thereof
|
CA2927806C
(en)
|
2013-11-27 |
2023-01-10 |
Redwood Bioscience, Inc. |
Hydrazinyl-pyrrolo compounds and methods for producing a conjugate
|
UY35874A
(en)
|
2013-12-12 |
2015-07-31 |
Novartis Ag |
A PROCESS FOR THE PREPARATION OF A COMPOSITION OF PEGILATED PROTEINS
|
WO2015130963A2
(en)
|
2014-02-27 |
2015-09-03 |
Xenetic Biosciences, Inc. |
Compositions and methods for administering insulin or insulin-like protein to the brain
|
US10293043B2
(en)
|
2014-06-02 |
2019-05-21 |
Armo Biosciences, Inc. |
Methods of lowering serum cholesterol
|
WO2015191781A2
(en)
|
2014-06-10 |
2015-12-17 |
Amgen Inc. |
Apelin polypeptides
|
CA2949985C
(en)
|
2014-06-12 |
2023-10-17 |
Ra Pharmaceuticals, Inc. |
Modulation of complement activity
|
WO2016028523A2
(en)
|
2014-08-22 |
2016-02-25 |
Sorrento Therapeutics, Inc. |
Antigen binding proteins that bind cxcr3
|
WO2016033555A1
(en)
|
2014-08-28 |
2016-03-03 |
Halozyme, Inc. |
Combination therapy with a hyaluronan-degrading enzyme and an immune checkpoint inhibitor
|
JP6625627B2
(en)
|
2014-10-14 |
2019-12-25 |
ハロザイム インコーポレイテッド |
Compositions of adenosine deaminase-2 (ADA2), variants thereof and methods of using the same
|
MX2017004838A
(en)
|
2014-10-14 |
2017-10-16 |
Armo Biosciences Inc |
Interleukin-15 compositions and uses thereof.
|
EP3209320B1
(en)
|
2014-10-22 |
2023-03-08 |
Armo Biosciences, Inc. |
Methods of using interleukin-10 for treating diseases and disorders
|
KR20240024362A
(en)
|
2014-10-24 |
2024-02-23 |
브리스톨-마이어스 스큅 컴퍼니 |
Modified fgf-21 polypeptides and uses thereof
|
EP3215193B1
(en)
|
2014-11-06 |
2023-10-04 |
PharmaEssentia Corporation |
Dosage regimen for pegylated interferon
|
US20160151511A1
(en)
|
2014-12-02 |
2016-06-02 |
Antriabio, Inc. |
Proteins and protein conjugates with increased hydrophobicity
|
CN104491843B
(en)
*
|
2015-01-23 |
2017-09-12 |
石药集团百克(山东)生物制药有限公司 |
A kind of polyethyleneglycol modified rhG CSF active pharmaceutical compositions
|
US9937222B2
(en)
|
2015-01-28 |
2018-04-10 |
Ra Pharmaceuticals, Inc. |
Modulators of complement activity
|
WO2016126615A1
(en)
|
2015-02-03 |
2016-08-11 |
Armo Biosciences, Inc. |
Methods of using interleukin-10 for treating diseases and disorders
|
EP3265491A1
(en)
|
2015-03-03 |
2018-01-10 |
Xoma (Us) Llc |
Treatment of post-prandial hyperinsulinemia and hypoglycemia after bariatric surgery
|
CN107849108A
(en)
*
|
2015-03-03 |
2018-03-27 |
阿瓦隆生物制品有限公司 |
The IL 11 of Pegylation composition and method
|
EP3277716B1
(en)
|
2015-04-03 |
2020-06-24 |
XOMA Technology Ltd. |
Treatment of cancer using inhibitors of tgf-beta and pd-1
|
WO2016167291A1
(en)
|
2015-04-13 |
2016-10-20 |
国立研究開発法人産業技術総合研究所 |
Cyclized cytokine and method for producing same
|
JP7245649B2
(en)
|
2015-05-01 |
2023-03-24 |
アリスタ ファーマスーティカルス インク. |
Adiponectin peptidomimetics for treating eye diseases (cross-reference to related applications)
|
EP3302547A1
(en)
|
2015-05-28 |
2018-04-11 |
Armo Biosciences, Inc. |
Pegylated interleukin-10 for use in treating cancer
|
AU2016304588A1
(en)
|
2015-08-06 |
2018-02-15 |
Xoma (Us) Llc |
Antibody fragments against the insulin receptor and uses thereof to treat hypoglycemia
|
JP7053453B2
(en)
|
2015-08-25 |
2022-04-12 |
アルモ・バイオサイエンシーズ・インコーポレイテッド |
How to use interleukin 10 to treat diseases and disorders
|
RU2020111229A
(en)
*
|
2015-09-18 |
2020-06-08 |
Юниверсити Оф Миязаки |
LONG-ACTING ADRENOMEDULLIN DERIVATIVE
|
CA3000697A1
(en)
|
2015-10-01 |
2017-04-06 |
Amgen Inc. |
Treatment of bile acid disorders
|
US10935276B2
(en)
|
2015-10-20 |
2021-03-02 |
Steven Michalski |
Air mixing device
|
ES2901769T3
(en)
|
2015-12-08 |
2022-03-23 |
Biomarin Pharm Inc |
Use of c-type natriuretic peptide variants to treat osteoarthritis
|
KR20180094913A
(en)
|
2015-12-16 |
2018-08-24 |
라 파마슈티컬스 인코포레이티드 |
Regulator of complement activity
|
JP6883590B2
(en)
|
2016-01-29 |
2021-06-09 |
ソレント・セラピューティクス・インコーポレイテッドSorrento Therapeutics, Inc. |
Antigen-binding protein that binds to PD-L1
|
JP7148493B2
(en)
|
2016-08-01 |
2022-10-05 |
ゾーマ (ユーエス) リミテッド ライアビリティ カンパニー |
Parathyroid hormone receptor 1 (PTH1R) antibodies and uses thereof
|
US10858428B2
(en)
|
2016-09-28 |
2020-12-08 |
Xoma (Us) Llc |
Antibodies that bind interleukin-2 and uses thereof
|
US11129906B1
(en)
|
2016-12-07 |
2021-09-28 |
David Gordon Bermudes |
Chimeric protein toxins for expression by therapeutic bacteria
|
JP7301741B2
(en)
|
2016-12-07 |
2023-07-03 |
ラ ファーマシューティカルズ インコーポレイテッド |
modulator of complement activity
|
MX2019008449A
(en)
|
2017-02-08 |
2019-09-09 |
Bristol Myers Squibb Co |
Modified relaxin polypeptides comprising a pharmacokinetic enhancer and uses thereof.
|
SG11201912071QA
(en)
|
2017-06-22 |
2020-01-30 |
Catalyst Biosciences Inc |
Modified membrane type serine protease 1 (mtsp-1) polypeptides and methods of use
|
KR102020995B1
(en)
|
2017-10-30 |
2019-09-16 |
한국코러스 주식회사 |
A method of preparing gcsf and polyol_conjugated conjugates with high yield
|
EP3732254A4
(en)
|
2017-12-26 |
2021-12-22 |
Becton, Dickinson and Company |
Deep ultraviolet-excitable water-solvated polymeric dyes
|
US11732016B2
(en)
|
2017-12-27 |
2023-08-22 |
Council Of Scientific & Industrial Research |
Polypeptide exhibiting granulocyte-colony stimulating factor activity
|
EP3765484A4
(en)
*
|
2018-03-14 |
2021-12-22 |
Ba, Yong |
Pegylated antifreeze proteins and methods of making and using the same
|
US10844228B2
(en)
|
2018-03-30 |
2020-11-24 |
Becton, Dickinson And Company |
Water-soluble polymeric dyes having pendant chromophores
|
WO2019209473A1
(en)
|
2018-04-24 |
2019-10-31 |
Amgen Inc. |
Method for making injectable pharmaceutical compositions
|
US20190351031A1
(en)
|
2018-05-16 |
2019-11-21 |
Halozyme, Inc. |
Methods of selecting subjects for combination cancer therapy with a polymer-conjugated soluble ph20
|
KR102167755B1
(en)
|
2018-05-23 |
2020-10-19 |
주식회사 큐어바이오 |
Fragmented GRS polypeptide, mutants thereof and use thereof
|
CA3107332A1
(en)
|
2018-07-22 |
2020-01-30 |
Bioasis Technologies Inc. |
Treatment of lymphatic metastases
|
SG11202102427XA
(en)
|
2018-09-11 |
2021-04-29 |
Ambrx Inc |
Interleukin-2 polypeptide conjugates and their uses
|
EP3867265A1
(en)
|
2018-10-19 |
2021-08-25 |
Ambrx, Inc. |
Interleukin-10 polypeptide conjugates, dimers thereof, and their uses
|
US11613744B2
(en)
|
2018-12-28 |
2023-03-28 |
Vertex Pharmaceuticals Incorporated |
Modified urokinase-type plasminogen activator polypeptides and methods of use
|
CA3176021A1
(en)
|
2018-12-28 |
2020-07-02 |
Catalyst Biosciences, Inc. |
Modified urokinase-type plasminogen activator polypeptides and methods of use
|
JP2022520792A
(en)
|
2019-02-12 |
2022-04-01 |
アンブルックス,インコーポレイテッド |
Compositions, Methods, and Uses Containing Antibody-TLR Agonist Conjugates
|
US10882954B2
(en)
|
2019-04-11 |
2021-01-05 |
Sunbio Inc. |
Tertiary alkoxy polyethylene glycol and derivatives thereof
|
AU2020258384A1
(en)
|
2019-04-15 |
2021-11-04 |
Qwixel Therapeutics Llc |
Fusion protein composition(s) comprising targeted masked type I interferons (IFNA and IFNB) and an antibody against tumor antigen, for use in the treatment of cancer
|
EP3955965A1
(en)
*
|
2019-04-15 |
2022-02-23 |
NOF Corporation |
Conjugate of bio-related substance and block polymer, and block polymer derivative for obtaining said conjugate
|
IL296099A
(en)
|
2020-03-11 |
2022-11-01 |
Ambrx Inc |
Interleukin-2 polypeptide conjugates and methods of use thereof
|
EP4121448A2
(en)
|
2020-03-20 |
2023-01-25 |
Amgen Inc. |
Determination of free n-terminus of pegfilgrastim using an acid protease
|
US20210355468A1
(en)
|
2020-05-18 |
2021-11-18 |
Bioasis Technologies, Inc. |
Compositions and methods for treating lewy body dementia
|
US20210393787A1
(en)
|
2020-06-17 |
2021-12-23 |
Bioasis Technologies, Inc. |
Compositions and methods for treating frontotemporal dementia
|
WO2022040596A1
(en)
|
2020-08-20 |
2022-02-24 |
Ambrx, Inc. |
Antibody-tlr agonist conjugates, methods and uses thereof
|
US11602598B1
(en)
*
|
2020-08-27 |
2023-03-14 |
Fresenius Kabi Deutschland Gmbh |
Prefilled syringe with pegfilgrastim having optimized dose and methods related thereto
|
CN112710826A
(en)
*
|
2020-11-17 |
2021-04-27 |
北京九强生物技术股份有限公司 |
Coating and sealing method for improving stability of reagent
|
US11952461B2
(en)
|
2021-03-22 |
2024-04-09 |
Sunbio, Inc. |
Siloxy polyethylene glycol and derivatives thereof
|
IL307282A
(en)
|
2021-04-03 |
2023-11-01 |
Ambrx Inc |
Anti-her2 antibody-drug conjugates and uses thereof
|
CN113214328B
(en)
*
|
2021-05-08 |
2022-06-28 |
宁波经济技术开发区弘翔生化科技有限公司 |
Double-aqueous-phase system and monosaccharide separation method based on double-aqueous-phase system
|
EP4155349A1
(en)
|
2021-09-24 |
2023-03-29 |
Becton, Dickinson and Company |
Water-soluble yellow green absorbing dyes
|
WO2024007016A2
(en)
|
2022-07-01 |
2024-01-04 |
Beckman Coulter, Inc. |
Novel fluorescent dyes and polymers from dihydrophenanthrene derivatives
|
WO2024044327A1
(en)
|
2022-08-26 |
2024-02-29 |
Beckman Coulter, Inc. |
Dhnt monomers and polymer dyes with modified photophysical properties
|